Pituitary adenylate cyclase-activating polypeptide: Protective effects in stroke and dementia.
Alzheimer’s disease
Amyloid beta protein
Dementia
Neurotrophin
Pituitary adenylate cyclase-activating polypeptide
Stroke
Journal
Peptides
ISSN: 1873-5169
Titre abrégé: Peptides
Pays: United States
ID NLM: 8008690
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
05
12
2019
revised:
24
04
2020
accepted:
18
05
2020
pubmed:
24
5
2020
medline:
10
6
2021
entrez:
24
5
2020
Statut:
ppublish
Résumé
Evidence shows that pituitary adenylate cyclase-activating polypeptide (PACAP) improves stroke outcomes and dementia. The blood-brain barrier (BBB) controls the peptide and regulatory protein exchange between the central nervous system and the blood; the transport of these regulatory substances across the BBB has been altered in animal models of stroke and Alzheimer's disease (AD). PACAP is a powerful neurotrophin that can cross the BBB, which may aid in the therapy of neurodegenerative diseases, including stroke and AD. PACAP may function as a potential drug in the treatment, prevention, or management of stroke and AD and other neurodegenerative conditions. Here, we review the effects of PACAP in studies on stroke and dementias.
Identifiants
pubmed: 32445876
pii: S0196-9781(20)30081-4
doi: 10.1016/j.peptides.2020.170332
pii:
doi:
Substances chimiques
ADCYAP1 protein, human
0
Neuroprotective Agents
0
Pituitary Adenylate Cyclase-Activating Polypeptide
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
170332Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.